Advocates Pushed for Increased Cancer Research Funding
Cancer advocates visited Capitol Hill to request federal funding and support for the Clinical Trial Modernization Act.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Should the federal government prioritize increased spending for cancer research and prevention programs?
More than 750 advocates recently gathered on Capitol Hill to lobby lawmakers for increased federal cancer research funding. The participants aimed to ensure cancer prevention and treatment remain national priorities.
Why it matters
Sustained funding is critical for maintaining long-term progress, as historical increases in federal research support have contributed to a 34% decline in cancer mortality rates over the last 30 years.
A 34% decline in cancer mortality over 30 years reflects the long-term impact of consistent federal research funding. The effectiveness of current legislative efforts to further reduce these rates remains under investigation.
The players
Mercy Campos
An advocate from Fontana who lobbied members of Congress for increased cancer research funding.
Norma Torres
A U.S. Representative whose staff met with advocates to discuss federal cancer research priorities.
American Cancer Society Cancer Action Network
An organization that advocates for evidence-based public policy and hosts annual summits to coordinate research lobbying efforts.
The details
The Clinical Trial Modernization Act aims to address persistent disparities in medical research by reducing barriers to access based on income and geography. By expanding enrollment opportunities for underrepresented populations, the legislation seeks to make clinical trial results more representative of the broader population.
Timeline
September 2026: Advocates held Lobby Day events on Capitol Hill.
Health Landscape
This lobbying effort seeks to secure the resources necessary to continue the research initiatives supported by the National Cancer Institute. It highlights the transition from broad population-level survival gains to targeting remaining disparities in access and trial participation.
If you are interested in clinical trial participation, you may want to discuss current enrollment options and eligibility criteria with your physician. Staying informed about legislative developments can also help you understand how potential changes in access may affect your future care.
The takeaway
Consistent research funding remains a foundational pillar for improving long-term survival outcomes for patients with cancer. You can track progress on these research priorities by following policy updates from national health organizations.
Further reading
For more on the current landscape of research and care, visit Cancer.
Source note: This article includes information reported by Inland Empire Community News.
Live Poll
Should the federal government prioritize increased spending for cancer research and prevention programs?
